High expression levels of MAT2A are also observed in colorectal cancer, leukemia, lymphoma, nasopharyngeal carcinoma, melanoma, ovarian carcinoma, prostate adenocarcinoma and breast cancer than in their corresponding normal tissues [22]. This evidence concerns the gene MAT2A and nasopharyngeal carcinoma.